TG100572

Description	in vitro: TG100572 inhibited vascular endothelial cell proliferation in vitro (ED50= 610 ± 71 nM, mean ± SEM, N= 3) and blocked VEGF-induced phosphorylation of extracellular signal-regulated kinase (ERK), a signaling event in VEGF-induced mitogenesis. Additionally, TG100572 induced apoptosis in rapidly proliferating, but not quiescent, endothelial cell cultures . TG100572 inhibits downstream molecules involved in the vascular endothelial growth factor (VEGF) signaling pathway resulted in markedly diminished levels of HSV-induced angiogenesis and significantly reduced the severity of SK lesions. in vivo: Mice that received daily intraperitoneal injections of TG100572 (5 mg/kg) developed smaller CNV lesions than those seen in vehicle-injected mice; measuring CNV area using image analysis techniques demonstrated a 40% reduction compared to the vehicle control group.TG100572-treated group also lost an average 11% of their body weight over the 14 day course of this study compared to the veh
Pathways	Angiogenesis/Protein Tyrosine Kinase
Targets	Src/Bcr Abl PDGFR VEGFR FGFR

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.